NEUP Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 5.31%, SMA50 8.07%, SMA200 -38.66%). The stock’s 14-day RSI is 60.43 (firm momentum), while the ATR of 0.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -79.63% below its high and over 19.62% above its low. Average 10-day trading volume of 39.21 thousand shares is below the 3-month average of 65.79 thousand, indicating normal recent market interest.

Neuphoria Therapeutics Inc. generated EPS of -$23.89 over the past year. Five-year average earnings growth is -20.01%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $21.00. The high target offers 947.9% upside. The low target suggests 528.74% downside. The mean target is $25.67. This offers 668.56% upside. Neuphoria Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended May 15, 2026, missed forecasts by -83.93%. The prior quarter beat by 37.5%. Over the last six quarters, Apple has recorded several small beats. These include -1493.62% in May 20, 2025.

Neuphoria Therapeutics Inc. has 5.39 million shares outstanding. The public float is 4.17 million shares, elevated short interest at 0.62% of float. This equals 33.19 thousand shares. The short ratio is 1.06 days. Institutional investors hold 59.62% of the float. Insiders own 7.7%.

Neuphoria Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.68. This means the shares are trading below this model’s fair value.

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) closed at $3.39 USD, gaining $0.03 (0.89%) from the previous close of $3.36. The stock is currently mid-range between its 52-week high and low $3.19 and $21.40. With a market capitalization of about $18.32 million, Neuphoria Therapeutics Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.75). Key stats such as the average daily volume over the past year has been around 66.13 thousand shares, volume is running light vs its 52-week average. Headquartered in Burlington, MA, Neuphoria Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Spyridon Papapetropoulos, the company employs approximately 8 people and listed since December 16, 2021. Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials.

Neuphoria Therapeutics Inc. trades at a P/E ratio of -0.31, slightly below the S&P 500 average, with a price-to-sales ratio of -1.75 and a price-to-book ratio of 0.62 suggesting the stock is closer to book value. The P/FCF stands at 0.31, also below market averages.

Our AI price prediction model suggests that Neuphoria Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.97%, with price expected at $2.84 by August 04, 2026, within a range of $2.54 to $3.10 3-Month Outlook: Projected fall of -43.11%, reaching $1.90 by October 19, 2026, with a range of $1.27 to $2.28. 1-Year Outlook: Projected loss of -41.62%, with price at $1.95 by July 21, 2027, within a range of $0.00 to $0.00.

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) shares are flat 3.87% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Neuphoria Therapeutics Inc. trading at a premium to the broader market with a P/E of -0.31. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $24.50, suggesting 633.53% upside. Our AI forecast model points to short-term weakness (-14.97% over two weeks), a medium-term fall (-43.11% over three months), and a longer-term loss (-41.62% over one year), with expected trading ranges indicating moderate volatility.